Wellcome Leap’s Power Play: Industry Titans Join to Engineer Health Breakthroughs

SAN DIEGO, Sept. 09, 2026 -- Wellcome Leap, the U.S. nonprofit founded by the Wellcome Trust to function as a “breakthrough engine for human health,” today announced a significant enhancement to its leadership, appointing biopharmaceutical veterans John Young and Thomas Glanzmann to its Board of Directors. The move signals a clear strategy to fuse its high-risk, high-reward research model with the seasoned operational and commercial expertise required to turn ambitious scientific goals into tangible global health solutions.

A Strategic Infusion of Industry Expertise

The appointments are less a routine governance update and more a calculated injection of execution-focused leadership. John Young’s 35-year career at Pfizer culminated in his role as Chief Business Officer and a member of the Executive Leadership Team. Critically, he chaired Pfizer’s COVID SWAT Team, giving him firsthand experience in mobilizing resources at speed and scale to address a global health crisis—a core tenet of Wellcome Leap’s mission.

“Throughout my career, I have seen what becomes possible when exceptional science is matched with urgency, clear goals, and the ability to operate at scale,” said John Young. “Wellcome Leap brings those elements together in a unique way.”

Thomas Glanzmann brings a complementary, yet equally vital, perspective. His career spans executive roles across medical technologies, diagnostics, and biopharmaceuticals, including serving as CEO of Grifols S.A. and co-founding the venture capital firm Medtech Ventures Partners. This diverse background provides a panoramic view of the healthcare ecosystem, from identifying nascent technologies to navigating the complexities of global market delivery.

“Healthcare breakthroughs rarely emerge from a single discipline, organization, or way of thinking,” noted Thomas Glanzmann. “They require bold ideas, diverse expertise, collective problem-solving, and a willingness to take on challenges where the path forward is not obvious.”

For an organization designed to de-risk the “seemingly impossible,” the addition of two leaders who have spent their careers making the possible profitable and scalable is a powerful statement of intent. Richard Gillingwater, Chairman of the Wellcome Leap Board, emphasized this, stating, “They have led organizations through significant growth and know what it takes to turn scientific advances into real-world impact.”

The 'Breakthrough Engine' Model in Action

Founded in 2020 with an initial $300 million from the Wellcome Trust, Wellcome Leap was created to operate differently from traditional research funding bodies. Inspired by the U.S. Defense Advanced Research Projects Agency (DARPA), it eschews open-ended grants in favor of milestone-driven programs with aggressive timelines, typically aiming for transformative results in five to ten years.

Under the leadership of CEO Regina E. Dugan, a former DARPA director, the organization has rapidly built what it claims is the largest and most quickly activatable research network in the world, connecting over 1.5 million researchers across more than 160 institutions on six continents. This network is the talent pool for its ambitious programs, each tackling a complex health challenge.

Its portfolio demonstrates a remarkable breadth and ambition:

• Human Organs, Physiology, and Engineering (HOPE): A $50 million program aiming to revolutionize drug testing and transplantation. Its goals include creating multi-organ platforms that can double the predictive accuracy of preclinical trials and, most audaciously, bioengineering a fully transplantable, non-rejected kidney within a decade.

• Women’s Health: With a commitment of over $250 million and a goal to secure $1 billion in philanthropic capital, this is a cornerstone of Leap's work. In partnership with Melinda French Gates's Pivotal, it is launching programs to halve stillbirth rates, reduce a woman's lifetime Alzheimer's risk by 50%, and cut the diagnosis-to-treatment time for heavy menstrual bleeding from five years to five months.

• Vaccine Development: An early success story emerged from a Leap-funded project at Caltech, which produced a new all-in-one vaccine for SARS-like betacoronaviruses, fast-tracked into Phase I clinical trials in 2022.

This “breakthrough engine” is fueled by substantial and growing capital. The Wellcome Trust has injected over $635 million to date, and strategic partnerships, such as a $60 million collaboration with Singapore’s Temasek Trust, amplify its financial firepower. The appointments of Young and Glanzmann are the next logical step: ensuring this capital and scientific output are translated efficiently.

Bridging the Gap from Lab to Life

The greatest challenge in medical innovation is not always the initial discovery but the perilous journey from the lab bench to the patient bedside. This “valley of death,” where promising research fails due to financial, regulatory, or logistical hurdles, is precisely what Wellcome Leap’s new board structure seems designed to address.

Young's experience as Pfizer's Chief Business Officer is critical here. That role is fundamentally about building the bridges between internal R&D and the outside world through partnerships, acquisitions, and commercial strategy. His leadership of the COVID SWAT Team provides a case study in navigating global supply chains, regulatory bodies, and manufacturing scale-up under extreme pressure. This is the exact skill set needed to guide Leap’s successful programs toward widespread availability.

Similarly, Glanzmann’s career is a study in translation. From leading a global plasma-derived medicine company like Grifols to investing in early-stage companies at Medtech Ventures, he understands the full lifecycle of a health product. His experience on the boards of giants like Novartis and Alcon provides deep insight into the governance and strategic pivots required to keep complex organizations on track. His expertise will be invaluable in helping Leap-funded projects design for manufacturability, market access, and regulatory approval from day one, rather than as an afterthought.

A New Blueprint for Philanthropic Impact

The creation of Wellcome Leap represents a strategic evolution for its parent organization, the Wellcome Trust. As part of its commitment to spend £16 billion by 2032 to solve urgent health challenges, the Trust has designated Leap as its primary vehicle for high-speed, targeted “Solutions.” This complements the Trust’s traditional support for foundational “Discovery” research.

This model moves beyond passive funding and into the realm of active, systemic intervention. By setting audacious goals, hand-picking multidisciplinary teams, and enforcing accountability through milestones, the organization is not just sponsoring science—it is attempting to engineer it. The addition of Young and Glanzmann reinforces this engineering mindset, bringing in leaders who are experts in building and operating the complex machinery of the global healthcare industry.

Their arrival signifies that for Wellcome Leap, a breakthrough is not merely a published paper or a successful proof-of-concept. A true breakthrough is a solution that is scalable, accessible, and capable of changing lives around the world. With this fortified leadership, the organization is better equipped than ever to deliver on that ambitious promise.